SUMMARY Twenty five patients with motor neuron disease completed a double blind randomised cross over trial of RX77368, a stabilised TRH analogue, iv over 2 hours against saline. Temporary improvement in bulbar symptoms including speech, respiratory parameters, tongue movements and swallowing were seen. Fasciculations increased and spasticity decreased. Change in muscle force with drug was different from placebo but both increase and decrease in force were seen and did not result in detectable changes in function. Side effects were clinically significant in 50% of the patients and cleared within 12 hours. Prolonged rise of thyroxine and an increase in plasma levels of prolactin, thyroid stimulating hormone and growth hormone were seen and followed characteristic patterns.
All patients had weakness in the upper limbs. Four patients with PBP and one with ALS and prominent bulbar signs did not have weakness in the lower limbs. Onset of disease was obtained on careful questioning. Severe incapacity (17 cases) was defined as the presence of one or more of the following: unintelligible or nearly unintelligible speech and/or very impaired swallowing with easy choking or aspiration and inability to cough (n = 6), seriously impaired walking (less than 100 yards, frame or wheel chair required) (n = 8), inability to manipulate objects usefully with the dominant upper limb (n = 1), inability to perform activities of daily living unaided (feeding, bathing, toileting, dressing) (n = 2). Mean Norris scale score30 was (range 36-85).
Assessments
All patients had a full general medical examination including haematological, renal, hepatic, cardiovascular and endocrine investigation. Neurological examination included detailed assessment of muscle force both with the Medical Research Council scale31 and with a hand held dynamometer (Penny and Giles Transducers Ltd, Dorset, UK).32 Twenty one muscle groups were assessed with the latter in the controlled study, by the same examiner, in standard positions for force testing in each patient. They included neck flexion, right and left shoulder abduction, elbow extension and flexion, wrist extension, finger extension, index finger abduction, thumb abduction, hip flexion, knee extension and foot dorsiflexion. Maximal voluntary isometric contraction (MVC) was defined as the highest force after three satisfactory trials with adequate auditory stimulation32 which were all recorded. Spasticity was scored clinically ( Radioimmunoassays of thyroxine (T4), tri-iodothyronine (T3), thyroid stimulating hormone (TSH), prolactin (PRL), growth hormone (GH) and cortisol were all performed in the endocrine laboratory at Westminster Hospital. Procedure All patients were admitted to hospital. The two normal volunteers received doses ranging from 255 pg to 1730,pg. In the open pilot study five patients were given intravenous infusions of RX77368 in doses ranging from 0 10mg/kg to I mg/kg over 100 to 199 minutes. Twenty-six patients entered the double blind, placebo controlled, randomised crossover trial; three of them had taken part in the pilot study. MVC, VC, PF, MIP and MEP were measured daily for the first 5 days and also five times over 24 hours mimicking recordings during infusions. For respiratory parameters measurements over 24 hours were used as a baseline (fig 2, table 1 ). On days S and 12, 300 pg/kg of RX77368 over 2 hours or saline were given in random order. Patients were fasted for 9 hours prior to the infusions. Measurements of MVC and respiratory parameters were performed immediately before infusion, at I hour, at the end of it and again [5] [6] [7] hours and 24 hours after it. Spasticity and fasciculations were scored before, at the end of, and up to 24 hours after infusion. Assessment of speech and other bulbar mediated functions was performed for each infusion at least three times; before, at the end and 4-8 hours after it. Walking was timed before and at the end of the infusions. Blood pressure and skin temperature were monitored throughout the infusions. In the bulbar subset there was evidence of onger voice and easier significant improvement in total range of tongue fter infusion.
movements at the end of drug infusion (Mannrespiratory parame-Whitney U Test, p = 0-04) and of swallowing 4 hours the drug (table 1) . A after drug infusion (Mann-Whitney U Test, p = he drug was seen for 0-05). Palatal movement (repetitive elevation) was ibgroup, but the fall worse with the drug 4 hours after infusion (Mannwith placebo. This Whitney U Test, p = 005). ge in this parameter Fasciculations increased about 1 hour into the drug The main results of analysis of force are summarised in table 2. The total number of muscles with increase and decrease in force was significantly higher with drug, and for those showing no change was significantly higher with placebo. When expressing the total number of muscles with change in force as a percentage of the number of muscles tested in each patient the mean percentage of muscles with increase in force was 19 7 for the drug and 13-2 for placebo (split-plot ANOVA, p = 0-07). The mean percentage of muscles with decrease in force was 20-6 for the drug and 10 for placebo (split-plot ANOVA, p = 0 004). The mean number of muscles increasing in force per patient was 3-2 for drug and 2-1 for placebo (split-plot ANOVA, p = 0-06). The mean number of muscles decreasing in force was 3-0 for drug and 1 6 for placebo (split-plot ANOVA, p = 0-003).
Analysis by muscle group shows that for the majority (15) of the 21 muscle groups tested increase and decrease in force was seen in more patients following drug than following placebo infusion (between treatment comparison). A within treatment comparison showed no real trend in respect of the direction of the change in force over the muscle groups after either drug or placebo treatment (table 2) .
Analysis by patient showed that in a greater proportion of patients more muscles changed in force with the drug than with placebo. The number of patients showing more muscles increasing and decreasing in force with drug than with placebo is close (14 and 16 respectively, There was a minor but statistically significant reduction in Norris scale score (split-plot ANOVA, p = 0-034) with the drug related entirely to increase in fasciculations.
There was no difference in timed walking between placebo and drug.
No significant difference (split-plot ANOVA) between placebo and drug was found for (1) decrement in amplitude of compound muscle action potential (MAP) of ADM with repetitive stimulation of the ulnar nerve at I and 2 hours after starting infusions 9 (n = 12); (2) peak to peak amplitude of the MAP of ADM measured before and at 1 hour and 2 hours after starting infusion (n = 15); (3) distal motor latency to ADM (n = 17) and maximal motor nerve conduction velocity (n = 16) of the elbow-wrist segment of the ulnar nerve measured before and at the end of infusion.
B. ENDOCRINE FINDINGS
Pilot study Only three of the four patients given two infusions were evaluated. In two of the three the maximum response of TSH to RX77368 was less for the second infusion than for the first, and the dose-response curve is shifted to the right (fig5 Panel D). This is despite the fact that they received a larger total dose during the second infusion than the first. In After the infusion, levels rapidly decline to normal within 6 hours. RX77368 stimulates the integrated secretion of GH (p < 0 05) (fig 7) . The maximum level of GH was 10 1 + 14 pg/l at 120 minutes after the start of the infusion. Cortisol (fig 7) was not significantly affected by RX77368. The expected diurnal decline in cortisol did not occur in either the RX77368 or placebo group.
Thyroxine (fig 6) levels rose within 60 minutes of the start of the infusion, and the increase was significant by 120 minutes. Levels rose even higher 6 hours after the end of the infusion and did not return to normal until 72 hours after the end of the infusion. T3 levels rose earlier than T4, and the increase was significant by 90 minutes. T3 levels returned to normal within 48 hours.
Side effects were clinically important in 13 patients (50%). They included cold and warm sensations, nausea, shivering, paraesthesia and dysaesthesia, vomiting, irritability, sweating, tiredness, nasal secretion, 53 We 
of speech. Variations in bulbar involvement, degree of spasticity, pyramidal weakness and patchy lower motor neuron weakness result in marked variations in clinical picture and functional capacity from patient to patient. There are also fluctuations in performance in each patient over time. The test situation, with 2 hour infusions and a number of measurements being performed, is likely to introduce further variation. Attempts to control for these factors included random cross-over design and appropriate baseline measurements in each patient, against which both drug and saline infusions were compared. The infusions were separated by 7 days, an interval deemed adequate from other data from our group and treatment x period interaction was considered in the statistical analysis. 38 The double blind nature of the trial may be questioned because of the side effects of the drug. However in 50% of the patients they were not clinically significant and a few patients had side effects with placebo (nausea, vomiting). Measurements that showed the most clear drug effect (speech, respiration) are unlikely to have had observer bias (see methods).
The most striking beneficial effect of RX77368 was improvement in predominantly spastic dysarthria both in clarity and volume, as described for native TRH (fig 3) . 4 The power of the trial to detect the mean 41 % improvement seen with a mean standard deviation of the difference of 20% was greater than 0 9. Subjective improvement in speech in seven out of 12 patients given native TRH by Caroscio et al1 5 was not confirmed by analysis of their tape recordings. The cross-over intervals in this trial were short, 72 hours between drug and placebo and 96 hours between iv and sc routes. Mitsumoto et al'4 and Brooke et al'6 only measured the time required to repeat three syllables ten times and repetition of a standard sentence respectively. The effect lasted up to 72 hours in our patients and was reported for up to 48 hours by Caroscio's patients. 15 The effects on respiratory parameters (table 1, fig 2) might also be useful. Improvement in vital capacity with native TRH has been noted by some4 80 but not by others. '4 1516 Transient improvements in range of tongue movements and swallowing were noted both subjectively and objectively in patients with bulbar syndrome with the methods used here. Palatal movement paradoxically showed deterioration after infusion. Improvement in force of tongue elevation and in facial muscles has been reported for native TRH. 0 Data on muscle force show that a similar number of muscles, muscle groups and patients have increase as have decrease in force with the drug at the dose used (table 2, fig4). The effect on force was modest, rarely extended beyond 6 hours after infusion and was seldom clinically useful. Only in four out of 14 patients (29%) who had more muscles that increased in force with drug than with placebo was the difference of four or more muscles. Increase in fasciculations, lack of an effect on fatigability (fig 1) and lack of decrement of the MAP of ADM argue against an action of the drug on the neuromuscular junction and are consistent with a direct or indirect action on anterior horn cells. Lack of effect on maximal motor nerve conduction velocity and distal motor latency are against an action on distal fastest conducting motor fibres. A complex effect at various levels, including blood vessels and muscle, cannot be ruled out. In some muscles we observed both increase and decrease in force with the drug, in any order. The direction of change in force in any muscle in an individual patient could not be predicted at the dose used, that is did not differ from direction of change in force with placebo (table 2, within group analysis). The "autorefractory state" described for native TRH54 with initial increase in force and later decrease in force with subsequent doses was not observed by us. Decrease in force was seen in some muscles with small doses and further decrease with subsequent doses (fig 1) . It is uncertain whether differences in methodology or in the actions of TRH and RX77368 account for this discrepancy. Faden etal48 suggest that neurological recovery after spinal cord injury in cats improves with TRH and with an analogue with a substitution in the pyroglutamyl ring of the tripeptide (CG3509) but not with another analogue which has modifications to both the pyroglutamyl and prolineamide rings (MK771). Future identification of the mechanisms underlying change in force with TRH and analogues and in particular, its direction, in patients with motor neuron disease, is needed. There is no compelling reason to assume that pharmacological agents will have a similar effect on all muscle groups. The anatomical location and synaptic connectivity of anterior horn cells in lamina IX of Rexed is said to be different for proximal and distal muscles55 and the fibre type composition of different muscles varies. 56 The findings on muscle force are consistent with the lack of observable difference between drug and placebo in both timed walking and Norris scale. However, several patients reported general improvement in strength and in various activities, including walking, with the drug. The distance timed was only 6 metres and the Norris scale may not be sensitive enough to detect this subjective impression. 57 This trial was designed to establish the acute effects of the analogue at a dose judged from the pilot study to maximise neurological action with an acceptable degree of clinical side effects. Prolonged therapy should be explored to establish whether the improvements seen can be maintained. Although others have failed to show a change in the course of the illness so far with native TRH14 16 76 any symptomatic effect that might improve quality of life would be important. In addition, any possible effect of this and other TRH analogues on the course of the disease is worth studying.
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